A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Cedazuridine/decitabine (Primary) ; Talazoparib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
Most Recent Events
- 21 Mar 2024 Status changed from recruiting to completed.
- 30 Nov 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 30 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 23 Dec 2024.